55686-91-4

Basic information

• Product Name: 2-PIPERAZIN-1-YL-QUINOXALINE
• Synonyms: 2-PIPERAZIN-1-YL-QUINOXALINE
• CAS NO: 55686-91-4
• Molecular Formula: C₁₂H₁₄N₄
• Molecular Weight: 214.271
• Mol File: 55686-91-4.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 407.6±35.0 °C(Predicted)
• Appearance: /
• Density: 1.201±0.06 g/cm3(Predicted)
• PKA: 8.58±0.10(Predicted)
• CAS DataBase Reference: 2-PIPERAZIN-1-YL-QUINOXALINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-PIPERAZIN-1-YL-QUINOXALINE(55686-91-4)
• EPA Substance Registry System: 2-PIPERAZIN-1-YL-QUINOXALINE(55686-91-4)

Safety Data

• Hazardous Substances Data: 55686-91-4(Hazardous Substances Data)

Usage

Description

2-PIPERAZIN-1-YL-QUINOXALINE is a chemical compound that features a quinoxaline ring with a piperazine group attached at the 2-position. It is widely recognized in medicinal chemistry as a fundamental building block for the development of diverse pharmaceutical compounds. The presence of the piperazine group in 2-PIPERAZIN-1-YL-QUINOXALINE facilitates interactions with biological targets, rendering it an advantageous scaffold for drug design. Its potential applications extend beyond medicinal chemistry, as it has been investigated for its antipsychotic and anxiolytic properties, as well as its antimicrobial and antitumor capabilities, highlighting its versatility in the medical and pharmaceutical sectors.

Uses

Used in Pharmaceutical Industry:
2-PIPERAZIN-1-YL-QUINOXALINE is utilized as a key building block for the synthesis of pharmaceutical compounds due to its ability to interact with biological targets, which is crucial for drug design and development.
Used in Medicinal Chemistry Research:
As a valuable scaffold, 2-PIPERAZIN-1-YL-QUINOXALINE is used in the research and development of new drugs, particularly those targeting psychiatric and neurological disorders.
Used in Antipsychotic and Anxiolytic Drug Development:
2-PIPERAZIN-1-YL-QUINOXALINE is employed as a potential agent in the creation of antipsychotic and anxiolytic medications, given its demonstrated potential in these therapeutic areas.
Used in Antimicrobial Applications:
2-PIPERAZIN-1-YL-QUINOXALINE is used as an antimicrobial agent, leveraging its ability to combat various types of infections and contributing to the development of new antibiotics.
Used in Antitumor Drug Development:
2-PIPERAZIN-1-YL-QUINOXALINE is applied in the development of antitumor drugs, capitalizing on its exhibited antitumor activities to potentially treat cancer.

Upstream product

• 1196-57-2 2-hydroxyquinoxaline 
• 95-54-5 1,2-diamino-benzene 
• 110-85-0 piperazine 
• 1448-87-9 2-chloroquinoxaline 

Downstream Products

• 1385829-25-3 4-{4-[2-(4-(quinoxalin-2-yl)piperazin-1-yl)ethyl]phenyl}thiazol-2-amine 
• 1385829-26-4 N-methyl-4-{4-[2-(4-(quinoxalin-3-yl)piperazin-1-yl)ethyl]phenyl}thiazol-2-amine 
• 1385829-27-5 5-methyl-4-{4-[2-(4-(quinoxalin-2-yl)piperazin-1-yl)ethyl]phenyl}thiazol-2-amine 
• 1385829-28-6 4-{4-[2-(4-(quinoxalin-2-yl)piperazin-1-yl)ethyl]phenyl}thiazol-2-ol 
• 1385829-29-7 2-{4-[4-(2,5-dimethylthiazol-4-yl)phenethyl]piperazin-1-yl}quinoxaline 
• 1385829-30-0 N,5-dimethyl-4-{4-[2-(4-(quinoxalin-2-yl)piperazin-1-yl)ethyl]phenyl}thiazol-2-amine 
• 1385829-31-1 2-{4-[4-(2-methylthiazol-4-yl)phenethyl]piperazin-1-yl}quinoxaline 
• 348134-14-5 9-[4-(4-quinoxalin-2-yl-piperazin-1-yl)-butyl]-9H-fluorene-9-carboxylic Acid-4-fluoro-benzylamide 
• 906090-50-4 methyl 2-({[4-(2-quinoxalinyl)-1-piperazinyl]carbonyl}amino)benzoate 
• 55686-71-0 5-fluoro-2-piperazin-1-yl-quinoxaline 

Relevant articles and documents

One-pot multicomponent synthesis of novel 2-(piperazin-1-yl) quinoxaline and benzimidazole derivatives, using a novel sulfamic acid functionalized Fe3O4 MNPs as highly effective nanocatalyst

The immobilization of sulfonic acid on the surface of Fe3O4 magnetic nanoparticles (MNPs) as a novel acid nanocatalyst has been successfully reported. The morphological features, thermal stability, magnetic properties, and other physicochemical properties of the prepared superparamagnetic core–shell (Fe3O4@PFBA–Metformin@SO3H) were thoroughly characterized using Fourier transform infrared (FTIR), X-ray diffraction (XRD), energy-dispersive X-ray spectroscopy (EDS), field-emission scanning electron microscopy (FESEM), transmission electron microscopy (TEM), thermogravimetric analysis–differential thermal analysis (TGA-DTA), atomic force microscopy (AFM), dynamic light scattering (DLS), Brunauer–Emmett–Teller (BET), and vibrating sample magnetometer (VSM) techniques. It was applied as an efficient and reusable catalyst for the synthesis of 2-(piperazin-1-yl) quinoxaline and benzimidazole derivatives via a one-pot multiple-component cascade reaction under green conditions. The results displayed the excellent catalytic activity of Fe3O4@PFBA–metformin@SO3H as an organic–inorganic hybrid nanocatalyst in condensation and multicomponent Mannich-type reactions. The easy separation, simple workup, excellent stability, and reusability of the nanocatalyst and quantitative yields of products and short reaction time are some outstanding advantages of this protocol.

Design, synthesis, and preliminary in vitro and in vivo pharmacological evaluation of 4-{4-[2-(4-(2-substitutedquinoxalin-3-yl)piperazin-1-yl)ethyl] phenyl}thiazoles as atypical antipsychotic agents

A series of 4-{4-[2-(4-(2-substitutedquinoxalin-3-yl)piperazin-1-yl)ethyl] phenyl} thiazoles were synthesized in an effort to prepare novel atypical antipsychotic agents. The compounds were designed, synthesized, and characterized by spectral data (IR, 1H NMR, and MS) and the purity was ascertained by microanalysis. The D2 and 5-HT2A affinity of the synthesized compounds was screened in vitro by radioligand displacement assays on membrane homogenates isolated from rat striatum and rat cortex, respectively. Furthermore, all the synthesized final compounds (10a-g; 11a-g; 12a-g) were screened for their in vivo pharmacological activity in Swiss albino mice. D2 antagonism studies were performed using climbing mouse assay model and 5-HT2A antagonism studies were performed using quipazine-induced head twitches in mice. It was observed that none of the new chemical entities exhibited catalepsy and 12d, 11f, and 10a were found to be the most active compounds with 5-HT2A/D2 ratio of 1.23077, 1.14286, and 1.12857, respectively, while the standard drug risperidone exhibited 5-HT2A/D2 ratio of 1.0989. Among the twenty one new chemical entities, three compounds (12d, 11f, and 10a) were found to exhibit better atypical antipsychotic activity as they were found to have higher Meltzer index than the standard drug risperidone.

Discovery of orally bioavailable and novel urea agonists of the high affinity niacin receptor GPR109A

A urea class of high affinity niacin receptor agonists was discovered. Compound 1a displayed good PK, better in vivo efficacy in reducing FFA in mouse than niacin, and no vasodilation in a mouse model. Compound 1q demonstrated equal affinity to GPR109A as niacin.